Related Experiment Video
Updated: Feb 6, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Current clostridium difficile treatments: Lessons that need to be learned from the clinical trials
E C Tampaki1,2, A Tampakis1,3, A Posabella4
1a Department of Propaedeutic Surgery , Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens , Greece.
Clostridium difficile infection (CDI) recurrences are a significant challenge, as current treatments are limited. New strategies like fidaxomicin, fecal microbiota transplantation, and monoclonal antibodies show promise in reducing CDI recurrence rates.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Microbiology
Background:
- Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea in adults.
- Current treatments for CDI lack approved options for managing recurrent infections, suggesting a need for multifaceted approaches, especially in severe cases.
Purpose of the Study:
- To review emerging strategies for managing recurrent Clostridium difficile infections.
- To evaluate the efficacy of novel therapeutic and biotherapeutic approaches in reducing CDI recurrence.
Main Methods:
- Review of clinical trials and research on new CDI treatments.
- Analysis of data on fidaxomicin, fecal microbiota transplantation, non-toxigenic C. difficile strains, and monoclonal antibodies.
- Consideration of lessons learned from previous clinical trials for interpreting future study results.
Main Results:
- Fidaxomicin demonstrates potential in reducing CDI recurrences.
- Biotherapeutic strategies, including fecal microbiota transplantation and competitive inhibition, are being investigated.
- Monoclonal antibodies targeting C. difficile toxins offer protection against infection recurrence.
Conclusions:
- A combination of treatment approaches may be necessary for severe CDI and recurrences.
- Careful interpretation of future study results is crucial for effective recurrence management.
- Long-term monitoring (at least 30 days post-treatment) is essential for evaluating new CDI strategies.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Avoidance Learning and Learned Helplessness
Avoidance learning occurs when an organism learns that a specific behavior can prevent an unpleasant outcome. For example, a student who receives a bad grade may start studying harder to avoid future poor grades. This behavior persists even when the negative outcome is no longer present. Avoidance learning is powerful because it maintains behavior in the absence of the...
Electrical Current

